Literature DB >> 16184470

Prostate cancer risk among men with diabetes mellitus (Spain).

A González-Pérez1, L A García Rodríguez.   

Abstract

OBJECTIVE: Observational studies have associated diabetes with a decreased risk of prostate cancer. We aimed to evaluate this association using the General Practitioner Research Database in the UK.
METHODS: Population based case-control study nested in a cohort.
RESULTS: We identified 2,183 incident cases of prostate cancer between January 1995 and December 2001. We found that diabetic patients had a decreased risk of prostate cancer (OR = 0.72; 95% CI: 0.59-0.87). This association was observed among treated diabetics (OR = 0.63; 95% CI: 0.50-0.80) but not among untreated diabetics (OR = 1.01; 95% CI: 0.73-1.40). Our results suggest that the observed reduced risk could be restricted to users of insulin or sulphonylureas.
CONCLUSION: Patients with diabetes have a decreased risk of prostate cancer. The role of antidiabetic treatment in this association warrants further research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16184470     DOI: 10.1007/s10552-005-4705-5

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  12 in total

1.  Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

Authors:  X-X He; S M Tu; M-H Lee; S-C J Yeung
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

2.  Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study.

Authors:  Jocelyn S Kasper; Yan Liu; Edward Giovannucci
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

3.  Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study.

Authors:  Ilir Agalliu; Miia Suuriniemi; Ludmila Prokunina-Olsson; Bo Johanneson; Francis S Collins; Janet L Stanford; Elaine A Ostrander
Journal:  Prostate       Date:  2008-05-15       Impact factor: 4.104

Review 4.  Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.

Authors:  Christopher B Chen; Maxim Eskin; Dean T Eurich; Sumit R Majumdar; Jeffrey A Johnson
Journal:  BMC Cancer       Date:  2018-01-10       Impact factor: 4.430

Review 5.  CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis.

Authors:  Jakob Starup-Linde; Oystein Karlstad; Stine Aistrup Eriksen; Peter Vestergaard; Heleen K Bronsveld; Frank de Vries; Morten Andersen; Anssi Auvinen; Jari Haukka; Vidar Hjellvik; Marloes T Bazelier; Anthonius de Boer; Kari Furu; Marie L De Bruin
Journal:  Curr Drug Saf       Date:  2013-11

Review 6.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review.

Authors:  Emily Herrett; Sara L Thomas; W Marieke Schoonen; Liam Smeeth; Andrew J Hall
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

7.  The use of metformin and the incidence of lung cancer in patients with type 2 diabetes.

Authors:  Brielan B Smiechowski; Laurent Azoulay; Hui Yin; Michael N Pollak; Samy Suissa
Journal:  Diabetes Care       Date:  2012-08-24       Impact factor: 19.112

8.  Long-term use of angiotensin receptor blockers and the risk of cancer.

Authors:  Laurent Azoulay; Themistocles L Assimes; Hui Yin; Dorothee B Bartels; Ernesto L Schiffrin; Samy Suissa
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.

Authors:  Maria E Ramos-Nino; Charles D MacLean; Benjamin Littenberg
Journal:  BMC Med       Date:  2007-06-21       Impact factor: 8.775

10.  Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan.

Authors:  Cheng-Chieh Lin; Jen-Huai Chiang; Chia-Ing Li; Chiu-Shong Liu; Wen-Yuan Lin; Teng-Fu Hsieh; Tsai-Chung Li
Journal:  BMC Cancer       Date:  2014-05-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.